Envudeucitinib
CAS 2417135-66-9
MF C22H18[2]H6N6O3 MW426.5 g/mol
N-[4-{2-methoxy-3-[1-(2H3)methyl-1H-1,2,4-triazol-3-yl]anilino}-5-(3,3,3-2H3)propanoylpyridin-2-yl] cyclopropanecarboxamide
N-(4-(2-methoxy-3-(1-(trideuteriomethyl)-1,2,4-triazol-3-yl)anilino)-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl)cyclopropanecarboxamide
N-[4-[2-methoxy-3-[1-(trideuteriomethyl)-1,2,4-triazol-3-yl]anilino]-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl]cyclopropanecarboxamide
Janus kinase inhibitor, anti-inflammatory, Fronthera U.S. Pharmaceuticals, psoriasis, FTP 637
Envudeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis. It is a selective tyrosine kinase 2 (TYK2) inhibitor developed by Fronthera U.S. Pharmaceuticals LLC and now owned by Alumis, Inc. for the treatment of autoimmune diseases. Envudeucitinib targets the TYK2 signaling pathway, which plays a crucial role in regulating multiple pro-inflammatory cytokines such as IL-12, IL-23, and type I interferons.[1][2]
PAT
- Crystalline forms of a tyk2 inhibitor and uses thereofPublication Number: WO-2024081603-A1Priority Date: 2022-10-10
- Crystalline forms of a tyk2 inhibitor and uses thereofPublication Number: WO-2024059529-A1Priority Date: 2022-09-12
- Tyk2 inhibitors and uses thereofPublication Number: WO-2023227946-A1Priority Date: 2022-05-27
PAT
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024081603&_cid=P11-MGGDZU-88200-1
PAT
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023227946&_cid=P11-MGGE36-91523-1
AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
| Clinical data | |
|---|---|
| Other names | FTP-637 |
| Identifiers | |
| IUPAC name | |
| CAS Number | 2417135-66-9 |
| PubChem CID | 158715582 |
| IUPHAR/BPS | 13205 |
| UNII | KD2MDJ4GAB |
| KEGG | D13123 |
| Chemical and physical data | |
| Formula | C22H18D6N6O3 |
| Molar mass | 426.506 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES | |
| InChI | |
References
- Deng L, Wan L, Liao T, Wang L, Wang J, Wu X, et al. (August 2023). “Recent progress on tyrosine kinase 2 JH2 inhibitors”. International Immunopharmacology. 121 110434. doi:10.1016/j.intimp.2023.110434. PMID 37315371.
- Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, et al. (2023). “Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway”. Journal of Cutaneous Medicine and Surgery. 27 (1_suppl): 3S – 24S. doi:10.1177/12034754221141680. PMID 36519621.
////////Envudeucitinib, Janus kinase inhibitor, anti-inflammatory, Fronthera U.S. Pharmaceuticals, psoriasis, FTP 637